Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of 89Zr-Df-crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)
Complete Title: iPREDICT Trial: A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, Scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy
Trial Phase: II
Investigator: Delphine Chen
The purpose of this study is to evaluate whether 89Zr-Df-crefmirlimab (other names 89Zr-crefmirlimab berdoxam and 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Keywords:
- Melanoma
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Carcinoma, Merkel Cell
- Carcinoma, Renal Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Delphine Chen
RG1121794
NCT05013099
iPREDICT Trial: A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, Scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy
Melanoma
Lung Carcinoma, Non-Small-Cell (NSCLC)
Carcinoma, Merkel Cell
Carcinoma, Renal Cell